

Cat. No. MHC-HE014

**Description**

<b>Source</b>	Recombinant Human HLA-A*03:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVVGADGVGK peptide.
<b>Accession</b>	NP_002107.3(HLA-A*03:01)&P61769(B2M)&VVVGADGVGK
<b>Molecular Weight</b>	The protein has a predicted MW of 35.26 kDa (HLA-A*03:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.
<b>Endotoxin</b>	Less than 1EU per µg by the LAL method.
<b>Purity</b>	>95% as determined by Bis-Tris PAGE >95% as determined by HPLC

**Formulation and Storage**


<b>Formulation</b>	Supplied as 0.22 µm filtered solution in 20mM Tris, 200mM NaCl (pH 8.0).
<b>Storage</b>	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

**Background**

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

**Assay Data****Bis-Tris PAGE**

Human HLA-A\*03:01&B2M&KRAS G12D (VVVGADGVGK) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

**SEC-HPLC**

The purity of Human HLA-A\*03:01&B2M&KRAS G12D (VVVGADGVGK) Monomer is greater than 95% as determined by SEC-HPLC.